Viking Therapeutics (VKTX) Misses Q1 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. META
10. TLT

Go back to Viking Therapeutics (VKTX) Misses Q1 EPS by 2c

Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

April 27, 2022 4:08 PM EDT

Conference call scheduled for 4:30 p.m. ET today

Completion of Enrollment in Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH Expected in 2H22   Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Ongoing; Results Expected by Year-End Quarter-End Cash Balance of $185M Provides Runway Through Multiple Clinical Catalysts

SAN DIEGO, April 27, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended... More